trending Market Intelligence /marketintelligence/en/news-insights/trending/_I8EHNSHNeMK4v9U36Kf1g2 content esgSubNav
In This List

VIVUS CEO to step down; interim CEO named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


VIVUS CEO to step down; interim CEO named

VIVUS Inc. will appoint Thomas King as interim CEO after Seth H. Z. Fischer steps down as CEO and board member, effective Dec. 31.

King has served as a director of the company since May 24. He served as president, CEO and director of Alexza Pharmaceuticals Inc. from June 2003 to August 2016, and has been an independent biotechnology consultant since August 2016.

Fischer will serve as a strategic adviser to the company through 2018 to ensure a smooth transition and continued advancement of the company's strategic initiatives.